1. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Issue 6 (June 2020) Authors: Tolaney, Sara M; Wardley, Andrew M; Zambelli, Stefania; Hilton, John F; Troso-Sandoval, Tiffany A; Ricci, Francesco; Im, Seock-Ah; Kim, Sung-Bae; Johnston, Stephen RD; Chan, Arlene; Goel, Shom; Catron, Kristen; Chapman, Sonya C; Price, Gregory L; Yang, Zhengyu; Gainford, M Corona; André, Fabrice Journal: Lancet oncology Issue: Volume 21:Issue 6(2020) Page Start: 763 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗